The failure of yet another late-stage study on its Alzheimer's disease candidate puts Cassava Sciences in a pickle with ...

Charles Schwab Investment Management Inc. cut its stake in shares of Cassava Sciences, Inc. (NASDAQ:SAVA – Free Report) by 11.6% in the 4th quarter, according to its most recent filing with the ...

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period. The S&P 500 dropped nearly 3% for the week, with losses in three of the ...

Another week of escalating tariff talks led to a slump across major U.S. stock market indices for the five-day trading period ...

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Topline results were announced from a phase 3 trial evaluating simufilam, an oral small molecule that targets the filamin A protein, for the treatment of mild to moderate Alzheimer disease (AD).